JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that the Company presented preclinical data from its novel adeno-associated virus (AAV) gene ...

The Association des optométristes du Québec (AOQ) regretfully announces that 85% of its members have decided to withdraw from ...

(Alliance News) - Syncona Ltd on Wednesday noted positive trial results for a portfolio company's gene therapy aimed at treating people with Gaucher's disease.

Visiting Nassau County on Tuesday, Gov. Kathy Hochul announced plans for the New York BioGenesis Park, a $430 million, ...

Gov. Kathy Hochul on Tuesday announced a $150 million investment in the new state-of-the-art therapy hub to be built on ...

Gov. Kathy Hochul on Tuesday announced a $150 million investment in a new state-of-the-art cell and gene therapy hub to be built on Long Island.

The posters are available on the Posters and Publications page of the Company’s website.

Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces upcoming oral and poster ...

Nvelop Therapeutics, a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of ...

Coave's proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid, ...

Data further validates the AnelloVector™ platform as the first gene delivery vector system based on the human commensal anellovirusCAMBRIDGE, ...

Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024 ...